Search
Close this search box.

Category

Category

Zenas BioPharma annonce la publication d’une étude de phase 2 sur l’obéxélimab, un traitement expérimental pour la maladie liée aux IgG4 (ML-IgG4), dans The Lancet Rheumatology

L’étude a montré que l’obéxélimab produisait une amélioration clinique rapide, forte et soutenue, y compris une rémission clinique complète, chez la plupart des patients atteints de ML-IgG4 active Les résultats soutiennent la poursuite du développement de l’obéxélimab pour le traitement de la ML-IgG4 et potentiellement d’autres maladies auto-immunes à médiation

Zenas BioPharma Publica Fase 2 do Estudo Clínico do Obexelimabe, um Tratamento Investigativo da Doença Relacionada à IgG4 (IgG4-RD), no The Lancet Rheumatology

Estudo revelou que o obexelimabe produziu melhora clínica rápida, forte e sustentada, incluindo remissão clínica completa, na maioria dos pacientes com IgG4-RD ativa Os resultados apoiam o desenvolvimento contínuo do obexelimabe para o tratamento de IgG4-RD e potencialmente outras condições autoimunes mediadas por células B WALTHAM, Mass., Aug. 02, 2023

Chikunga speaks out on Cape Town taxi-related violence

Transport Minister Sindisiwe Chikunga has noted with deep concern the recent incidents of violence in Cape Town related to law enforcement officials impounding taxis due to various infringements.In a statement on Thursday, the Minister strongly condemn…

Home Affairs opens selected offices on Saturday, 5 August 2023

Seven Home Affairs Offices to open on Saturday for clients to collect smart ID cards and passportsSeven Home Affairs offices will open on Saturday, 5 August 2023, from 08h00 to 13h00, to increase access to services mainly for clients who are unable to …

About Us

Promoting revolutionary values and uniting movements for South Africa’s economic freedom.

Newsletter

Enter your email address below to subscribe to my newsletter